By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galectin Therapeutics 

7 Wells Avenue
Suite #34
Newton  Massachusetts  02459  U.S.A.
Phone: 617-559-0033 Fax: 617-928-3450


Company News
Galectin Announces Pricing Of $9.8 Million Registered Direct Offering 11/20/2015 7:59:44 AM
Research Underlying Galectin's Development Of GR-MD-02 In Cancer Presented At The Society For Immunotherapy Of Cancer Annual Meeting 11/11/2015 8:04:31 AM
Galectin Reports Third Quarter 2015 Financial Results And Provides Business Update 11/9/2015 9:05:21 AM
Galectin Selected To Present At Cavendish Global Health Impact Forum 10/23/2015 8:09:39 AM
Galectin' GR-MD-02 To Be Studied In Combination With Keytruda In Patients With Metastatic Melanoma 10/19/2015 7:29:53 AM
Galectin Therapeutics' Executive Chairman To Discuss Silent Epidemic And Company's Role In Developing Treatments For NASH And Other Diseases At Robins Equity Research Roundup Conference 10/7/2015 2:19:08 PM
Galectin Therapeutics Executive Chairman Jim Czirr To Be Interviewed On "The Big Biz Show" 10/7/2015 11:11:35 AM
Galectin Therapeutics Begins Phase IIa Psoriasis Study With GR-MD-02 9/24/2015 8:04:45 AM
Galectin Therapeutics To Present At 2015 Ladenburg Thalmann Healthcare Conference 9/22/2015 8:26:56 AM
Galectin Therapeutics Announces Start Of Phase 2 Clinical Trial With GR-MD-02 In NASH With Advanced Fibrosis 9/16/2015 6:19:28 AM